CN110545817B - Gsk-3抑制剂 - Google Patents
Gsk-3抑制剂 Download PDFInfo
- Publication number
- CN110545817B CN110545817B CN201780084344.7A CN201780084344A CN110545817B CN 110545817 B CN110545817 B CN 110545817B CN 201780084344 A CN201780084344 A CN 201780084344A CN 110545817 B CN110545817 B CN 110545817B
- Authority
- CN
- China
- Prior art keywords
- pyrimidine
- yield
- esi
- nmr
- retention time
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662426631P | 2016-11-28 | 2016-11-28 | |
| US62/426,631 | 2016-11-28 | ||
| PCT/US2017/063231 WO2018098412A1 (en) | 2016-11-28 | 2017-11-27 | Gsk-3 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110545817A CN110545817A (zh) | 2019-12-06 |
| CN110545817B true CN110545817B (zh) | 2022-11-15 |
Family
ID=60655130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780084344.7A Active CN110545817B (zh) | 2016-11-28 | 2017-11-27 | Gsk-3抑制剂 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10752609B2 (https=) |
| EP (1) | EP3544613B1 (https=) |
| JP (1) | JP7114591B2 (https=) |
| KR (1) | KR102575990B1 (https=) |
| CN (1) | CN110545817B (https=) |
| ES (1) | ES2878078T3 (https=) |
| MA (1) | MA46889A (https=) |
| WO (1) | WO2018098412A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2850773T3 (es) * | 2016-11-28 | 2021-08-31 | Bristol Myers Squibb Co | Piridincarboxamidas como inhibidores de GSK-3 |
| WO2020132651A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
| EP3898616B1 (en) * | 2018-12-20 | 2024-10-02 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
| JP7676308B2 (ja) | 2018-12-20 | 2025-05-14 | アムジエン・インコーポレーテツド | Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド |
| US12540129B2 (en) | 2019-08-02 | 2026-02-03 | Amgen Inc. | KIF18A inhibitors |
| WO2021026099A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
| CN116178281B (zh) * | 2023-04-27 | 2023-07-21 | 中国药科大学 | 一种双功能免疫抑制剂及其制备方法和应用 |
| EP4709712A1 (en) * | 2023-05-10 | 2026-03-18 | Blueprint Medicines Corporation | Gsk3a inhibitors and methods of use thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101801958A (zh) * | 2007-07-19 | 2010-08-11 | 先灵公司 | 作为蛋白质激酶抑制剂的杂环酰胺化合物 |
| WO2012024179A1 (en) * | 2010-08-18 | 2012-02-23 | Merck Sharp & Dohme Corp. | Substituted amide derivatives as dgat-1 inhibitors |
| CN105849098A (zh) * | 2013-11-06 | 2016-08-10 | 百时美施贵宝公司 | Gsk-3抑制剂 |
| WO2016144792A1 (en) * | 2015-03-06 | 2016-09-15 | Alpharmagen, Llc | Alpha 7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0102438D0 (sv) | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| CN105849097A (zh) | 2013-11-06 | 2016-08-10 | 百时美施贵宝公司 | 取代的吡啶衍生物用作gsk-3抑制剂 |
| ES2850773T3 (es) | 2016-11-28 | 2021-08-31 | Bristol Myers Squibb Co | Piridincarboxamidas como inhibidores de GSK-3 |
-
2017
- 2017-11-27 CN CN201780084344.7A patent/CN110545817B/zh active Active
- 2017-11-27 KR KR1020197018285A patent/KR102575990B1/ko active Active
- 2017-11-27 JP JP2019528512A patent/JP7114591B2/ja active Active
- 2017-11-27 WO PCT/US2017/063231 patent/WO2018098412A1/en not_active Ceased
- 2017-11-27 EP EP17812188.5A patent/EP3544613B1/en active Active
- 2017-11-27 MA MA046889A patent/MA46889A/fr unknown
- 2017-11-27 US US16/463,467 patent/US10752609B2/en active Active
- 2017-11-27 ES ES17812188T patent/ES2878078T3/es active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101801958A (zh) * | 2007-07-19 | 2010-08-11 | 先灵公司 | 作为蛋白质激酶抑制剂的杂环酰胺化合物 |
| WO2012024179A1 (en) * | 2010-08-18 | 2012-02-23 | Merck Sharp & Dohme Corp. | Substituted amide derivatives as dgat-1 inhibitors |
| CN105849098A (zh) * | 2013-11-06 | 2016-08-10 | 百时美施贵宝公司 | Gsk-3抑制剂 |
| WO2016144792A1 (en) * | 2015-03-06 | 2016-09-15 | Alpharmagen, Llc | Alpha 7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190085114A (ko) | 2019-07-17 |
| ES2878078T3 (es) | 2021-11-18 |
| JP2019535788A (ja) | 2019-12-12 |
| US10752609B2 (en) | 2020-08-25 |
| CN110545817A (zh) | 2019-12-06 |
| WO2018098412A1 (en) | 2018-05-31 |
| JP7114591B2 (ja) | 2022-08-08 |
| MA46889A (fr) | 2019-10-02 |
| US20190315714A1 (en) | 2019-10-17 |
| EP3544613A1 (en) | 2019-10-02 |
| KR102575990B1 (ko) | 2023-09-08 |
| EP3544613B1 (en) | 2021-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110545817B (zh) | Gsk-3抑制剂 | |
| CN104379574B (zh) | 用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物 | |
| CN114437105B (zh) | 受体相互作用蛋白激酶1的抑制剂 | |
| CN108467369B (zh) | 作为激酶抑制剂的联芳基酰胺化合物 | |
| CN108602809B (zh) | 异噁唑烷衍生的受体相互作用蛋白激酶1(ripk 1)的抑制剂 | |
| CN104302634B (zh) | 用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物 | |
| JP6517928B2 (ja) | キナーゼ阻害剤として有用なインドールカルボキシアミド | |
| WO2021239133A1 (zh) | 作为axl抑制剂的嘧啶类化合物 | |
| CN104955456B (zh) | 作为分拣蛋白抑制剂的n-取代的-5-取代的邻氨甲酰苯甲酸 | |
| CN105849098A (zh) | Gsk-3抑制剂 | |
| AU2018217488A1 (en) | Aminotriazolopyridines as kinase inhibitors | |
| TW201444831A (zh) | 作爲突變ｉｄｈ抑制劑之３－嘧啶－４－基－□唑啶－２－酮 | |
| TW201718536A (zh) | 可作為ＴＮＦα調節劑之雜環化合物 | |
| CN103339110A (zh) | 作为cdk9抑制剂的取代的杂-联芳基化合物及其用途 | |
| CN107001329B (zh) | 作为激酶抑制剂的化合物和组合物 | |
| JP6592512B2 (ja) | 三環式アトロプ異性体の化合物 | |
| EA032361B1 (ru) | Трициклические соединения | |
| KR20240075952A (ko) | Fgfr 억제제 및 이의 사용 방법 | |
| CN110225912B (zh) | Gsk-3抑制剂 | |
| EA031310B1 (ru) | Производные пиперидина и азепина как модуляторы рецептора прокинетицина | |
| WO2023118253A1 (en) | Cyclohexane acid derivatives as lpa receptor inhibitors | |
| EP3368535A1 (en) | Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof | |
| CN114222744A (zh) | 可用作IL-12、IL-23和/或IFNα反应调节剂的咪唑并哒嗪化合物 | |
| HK40110192A (zh) | 4h-吡咯并[3，2-c]吡啶-4-酮化合物 | |
| HK40110212A (zh) | 4h-吡咯并[3，2-c]吡啶-4-酮化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |